Impact of HIV infection on overall survival among women with stage IV breast cancer in South Africa.
Breast cancer
HIV
Metastatic
sub-Saharan Africa
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
01
03
2021
accepted:
18
05
2021
pubmed:
15
6
2021
medline:
28
7
2021
entrez:
14
6
2021
Statut:
ppublish
Résumé
Advanced breast cancer (BC) at diagnosis is common in sub-Saharan Africa (SSA), including among women living with HIV (WLWH). In public hospitals across South Africa (SA), 10-15% of women present with stage IV BC, compared to < 5% in the United States (US); 20% of new BC diagnoses in SA are in WLWH. We evaluated the impact of HIV on overall survival (OS) among women with stage IV BC. We conducted a prospective cohort study of women diagnosed with stage IV BC between February 2, 2015 and September 18, 2019 at six public hospitals in SA. Multivariate Cox regression models were used to estimate the association between HIV status and OS. Among 550 eligible women, 147 (26.7%) were WLWH. Compared to HIV-negative BC patients, WLWH were younger (median age 45 vs. 60 years, p < 0.001), predominantly black (95.9% vs. 77.9%, p < 0.001), and more likely to have hormone receptor-negative (hormone-negative) BC (32.7% vs. 22.6%, p = 0.016). Most women received systemic cancer-directed therapy (80.1%). HIV status was not associated with treatment or OS (Hazard Ratio (HR) 1.13 [95%CI 0.89-1.44]). On exploratory subgroup analysis, WLWH and hormone-negative BC had shorter OS compared to HIV-uninfected women (1-year OS: 27.1% vs. 48.8%, p = 0.003; HR 1.94 [95%CI 1.27-2.94]; p = 0.002), which was not observed for hormone receptor-positive BC. HIV status was not associated with worse OS in women with stage IV BC in SA and cannot account for the poor survival in this cohort. Subgroup analysis revealed that WLWH with hormone-negative BC had worse OS, which warrants further investigation.
Identifiants
pubmed: 34125339
doi: 10.1007/s10549-021-06265-w
pii: 10.1007/s10549-021-06265-w
pmc: PMC9034410
mid: NIHMS1725109
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
285-296Subventions
Organisme : NCI NIH HHS
ID : R01CA250012
Pays : United States
Organisme : NCI NIH HHS
ID : K12CA226330
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA192627
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA094061
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA226330
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA13696
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA250012
Pays : United States
Organisme : NCI NIH HHS
ID : R01CA192627
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA013696
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
N Engl J Med. 1981 Jan 1;304(1):10-5
pubmed: 7432433
Afr Health Sci. 2011 Jun;11(2):279-84
pubmed: 21857862
Clin Breast Cancer. 2019 Jun;19(3):200-207.e1
pubmed: 30795886
Cancer. 1982 Dec 15;50(12):2747-50
pubmed: 6754067
Cancer. 2016 Aug 1;122(15):2399-407
pubmed: 27187086
J Glob Oncol. 2017 Apr;3(2):114-124
pubmed: 28706996
BMC Cancer. 2019 Nov 12;19(1):1091
pubmed: 31718602
Am J Clin Oncol. 1982 Jun;5(3):253-9
pubmed: 7044099
JAMA Oncol. 2019 Sep 01;5(9):e191742
pubmed: 31369037
J Clin Oncol. 2015 Jul 20;33(21):2376-83
pubmed: 26077242
Cancer. 2019 Aug 15;125(16):2868-2876
pubmed: 31050361
Cancer Causes Control. 2020 Apr;31(4):393-402
pubmed: 32124187
Afr J AIDS Res. 2016;15(1):67-75
pubmed: 27002359
Lancet Glob Health. 2020 Sep;8(9):e1203-e1212
pubmed: 32827482
Lancet Glob Health. 2016 Dec;4(12):e923-e935
pubmed: 27855871
Int J Cancer. 2020 Mar 1;146(5):1208-1218
pubmed: 31087650
Breast. 2018 Dec;42:23-30
pubmed: 30149234
Ann Intern Med. 2010 Oct 5;153(7):452-60
pubmed: 20921544
Clin Exp Metastasis. 2017 Dec;34(8):457-465
pubmed: 29288366
J Glob Oncol. 2016 Mar 30;2(5):284-291
pubmed: 28717714
Ann Surg Oncol. 2013 Sep;20(9):2828-34
pubmed: 23653043
Oncologist. 2019 Jul;24(7):933-944
pubmed: 30518615
Clin Breast Cancer. 2018 Oct;18(5):380-386
pubmed: 29622384
AIDS Patient Care STDS. 2014 Jul;28(7):358-64
pubmed: 24839993
Cancer. 1980 Feb 15;45(4):735-41
pubmed: 6986969
Int J Cancer. 2014 Nov 1;135(9):2173-82
pubmed: 24658866
J Clin Oncol. 2014 Aug 1;32(22):2344-50
pubmed: 24982448
Breast Cancer Res Treat. 2009 Apr;114(3):479-84
pubmed: 18463977
J Natl Cancer Inst. 1998 Aug 19;90(16):1205-11
pubmed: 9719081
Pan Afr Med J. 2016 Aug 24;24:324
pubmed: 28154679
JCO Glob Oncol. 2020 Apr;6:679-687
pubmed: 32348160
Breast Cancer Res Treat. 2013 Jul;140(1):177-86
pubmed: 23801159
Breast. 2019 Feb;43:123-129
pubmed: 30550925